Drugs / GS-1206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07703878 | Aug 2026 → Sep 2029 expected | neoplasm | Gilead Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-1206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07703878 ↗ |
| Route | Oral | “Administered Orally” NCT07703878 ↗ |